Advances in regenerative cardiology: Stem cells versus bioartificial tissues

Abstract

SC- and BAT-based therapies offer innovative avenues for repairing damaged myocardium. Their application could revolutionise treatment strategies for heart failure and post-infarction remodelling. However, clinical translation requires addressing immune compatibility, arrhythmic risk and manufacturing limitations. Interdisciplinary collaboration and regulatory standardisation are essential for their future clinical adoption.